logo
Plus   Neg
Share
Email

Myriad Genetics Raises FY18 Financial Guidance - Quick Facts

Myriad Genetics, Inc. (MYGN) announced, for fiscal 2018, the company expects adjusted earnings per share of $1.11-$1.16; and revenue in the range of $760-$770 million. For the third-quarter, the company expects adjusted earnings per share in the range of $0.26-$0.28; and revenue of $186-$188 million. The company estimates that the tax reform legislation will positively benefit fiscal 2018 full year adjusted earnings per share by approximately $0.06 with $0.02 recorded in the fiscal second quarter, and the remaining $0.04 benefit anticipated across the second half of fiscal 2018.

Second-quarter adjusted EPS was $0.31, up 19 percent from last year. Total revenues were $194.0 million, down 1% from prior year.

"We exceeded our financial expectations in the first half of fiscal year 2018 as a result of strong hereditary cancer volume trends, solid GeneSight revenue growth, and significant progress on our Elevate 2020 profitability program. Based upon this strong performance we are increasing our financial guidance for fiscal 2018," said Mark Capone, president and CEO, Myriad Genetics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT